Bavarian Nordic shares soar sharply on 62% revenue jump in Q1

Published 09/05/2025, 08:54
© Reuters.

Investing.com -- Shares in Bavarian Nordic (CSE:BAVA) surged sharply after the Denmark-based biotech company reported a strong jump in first-quarter revenues, driven by robust growth in both its Travel Health and Public Preparedness segments.

The company saw its Q1 revenue soar 62% year-on-year to DKK 1.34 billion, with Travel Health contributing DKK 680 million, up 52% year-over-year, supported by higher demand for rabies and tick-borne encephalitis (TBE) vaccines.

Public Preparedness revenue surged 83% to DKK 629 million, outperforming initial expectations due to the accelerated delivery of several large existing orders.

Other revenue totaled DKK 37 million.

Bavarian Nordic stock jumped around 13% in Copenhagen trading after the report. 

“A very strong first quarter for our Travel Health business, demonstrating a 52% growth year-over-year and puts us ahead of our strategic goal of an average annual growth rate of 10-12% for this part of the business until 2027," said Paul Chaplin, President and CEO of Bavarian Nordic. 

"We also recorded our first U.S. sales of the chikungunya vaccine after its approval in February and ahead of the April recommendation from ACIP. Our phased launch plan for the vaccine is progressing as planned with the first European markets coming online over the next couple of months while we also continue our efforts to expand the regulatory approvals to other territories."

EBITDA for the quarter came in at DKK 420 million, representing a 31% margin.

The company reaffirmed its full-year guidance, expecting revenue between DKK 5.7–6.7 billion and an EBITDA margin of 26–30%.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.